Rosiek-Biegus, M.; Pawłowicz, R.; Kopeć, A.; Kosińska, M.; Wrześniak, M.; Nittner-Marszalska, M.
Component-Resolved Evaluation of the Risk and Success of Immunotherapy in Bee Venom Allergic Patients. J. Clin. Med. 2022, 11, 1677.
https://doi.org/10.3390/jcm11061677
AMA Style
Rosiek-Biegus M, Pawłowicz R, Kopeć A, Kosińska M, Wrześniak M, Nittner-Marszalska M.
Component-Resolved Evaluation of the Risk and Success of Immunotherapy in Bee Venom Allergic Patients. Journal of Clinical Medicine. 2022; 11(6):1677.
https://doi.org/10.3390/jcm11061677
Chicago/Turabian Style
Rosiek-Biegus, Marta, Robert Pawłowicz, Agnieszka Kopeć, Magdalena Kosińska, Marta Wrześniak, and Marita Nittner-Marszalska.
2022. "Component-Resolved Evaluation of the Risk and Success of Immunotherapy in Bee Venom Allergic Patients" Journal of Clinical Medicine 11, no. 6: 1677.
https://doi.org/10.3390/jcm11061677
APA Style
Rosiek-Biegus, M., Pawłowicz, R., Kopeć, A., Kosińska, M., Wrześniak, M., & Nittner-Marszalska, M.
(2022). Component-Resolved Evaluation of the Risk and Success of Immunotherapy in Bee Venom Allergic Patients. Journal of Clinical Medicine, 11(6), 1677.
https://doi.org/10.3390/jcm11061677
